Skip to content
Lucitanib
Lucitanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target platelet-derived growth factor receptor alpha, proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 1, platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and fibroblast growth factor receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Duodenal ulcerD004381EFO_0004607K26—11——1
Peptic esophagitisD004942EFO_1001095—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8054———6
Non-small-cell lung carcinomaD00228912———2
Breast neoplasmsD001943EFO_0003869C50—2———2
Female genital neoplasmsD00583311———1
Urologic neoplasmsD014571C64-C6811———1
Ovarian neoplasmsD010051EFO_0003893C5611———1
Triple negative breast neoplasmsD06472611———1
Lung neoplasmsD008175C34.90—1———1
Small cell lung carcinomaD055752—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLUCITANIB
INNlucitanib
Description
E-3810 free base is a naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine. It has a role as an antineoplastic agent, a fibroblast growth factor receptor antagonist and a vascular endothelial growth factor receptor antagonist. It is a member of quinolines, an aromatic ether, a member of cyclopropanes, a primary amino compound and a naphthalenecarboxamide. It is a conjugate base of an E-3810(1+).
Classification
Small molecule
Drug classangiogenesis inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Identifiers
PDB—
CAS-ID1058137-23-7
RxCUI—
ChEMBL IDCHEMBL2220486
ChEBI ID65209
PubChem CID25031915
DrugBankDB11845
UNII IDPP449XA4BH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PDGFRA
PDGFRA
RET
RET
KIT
KIT
FLT1
FLT1
PDGFRB
PDGFRB
KDR
KDR
FGFR1
FGFR1
Organism
Homo sapiens
Gene name
PDGFRA
Gene synonyms
PDGFR2, RHEPDGFRA
NCBI Gene ID
5156
Protein name
platelet-derived growth factor receptor alpha
Protein synonyms
Alpha platelet-derived growth factor receptor, Alpha-type platelet-derived growth factor receptor, CD140 antigen-like family member A, CD140a, CD140a antigen, PDGF-R-alpha, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, platelet-derived growth factor receptor, alpha polypeptide
Uniprot ID
Q9UD28
Mouse ortholog
Pdgfra (18595)
platelet-derived growth factor receptor alpha (Q8C4N3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 229 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
18 adverse events reported
View more details